⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Daridorexant

داریدورکسانت

⚠ Unverified

🧠 Nervous SystemDual orexin receptor antagonist

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA214985 ATC N05CJ03

Market / country: 🇺🇸 USA

Quviviq (US)

🧮 Dose calculator

Disease / regimen

Insomnia · Regimen source: FDA Quviviq · 2.1

• No more than once a night, ≥7 h before awakening. Moderate hepatic impairment max 25 mg; severe not recommended. FDA Quviviq · 2.1 FDA Quviviq · 2.3

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Narcolepsy; hypersensitivity to daridorexant (angioedema). FDA Quviviq · 4

Warnings

• CNS depression and next-day impairment; sleep paralysis and hypnagogic hallucinations; complex sleep behaviours; compromised respiratory function; worsening depression and suicidal ideation. FDA Quviviq · 5

Formulations

25 mg tablet — tablet 🇺🇸 USA FDA Quviviq · 3
50 mg tablet — tablet 🇺🇸 USA FDA Quviviq · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Quviviq · 8.1
“Risk Summary There are no available data on QUVIVIQ use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Quviviq · 8.2
“Risk Summary Daridorexant is present in human breast milk in low amounts.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Quviviq · 8.4
“The safety and effectiveness of QUVIVIQ have not been established in pediatric patients.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Quviviq · 8.5
“Because QUVIVIQ can increase somnolence and drowsiness, patients, particularly the elderly, are at higher risk of falls [see Warnings and Precautions (5.1) ] .”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA214985
DailyMed (FDA label)FDA Quviviq
MedlinePlus (NIH)Daridorexant
WHO ATC/DDDN05CJ03
Darooyab (Iran)Daridorexant

🇮🇷 Not found in Iran list Darooyab · G-5578/Daridorexant

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Quviviq · 3 FDA Quviviq · 2.1 FDA Quviviq · 2.3 FDA Quviviq · 4 FDA Quviviq · 5 FDA Quviviq · 8.1 FDA Quviviq · 8.2 FDA Quviviq · 8.4 FDA Quviviq · 8.5 FDA Quviviq · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-5578/Daridorexant
Clinical review⚠ Unverified